Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MK-0812 Succinate 是一种选择性CCR2拮抗剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 597 | 现货 | ||
2 mg | ¥ 878 | 现货 | ||
5 mg | ¥ 1,490 | 现货 | ||
10 mg | ¥ 2,790 | 现货 | ||
25 mg | ¥ 4,670 | 待询 | ||
50 mg | 特惠询价 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,930 | 现货 |
产品描述 | MK-0812 Succinate is an effective and selective CCR2 antagonist. |
靶点活性 | MCP-1:4.5 nM |
体外活性 | MK-0812 not only fully blocks the shape change response to exogenous MCP-1 but also causes a monocyte forward scatter measurement below unstimulated or basal levels. The addition of MK-0812 to rhesus blood also inhibits MCP-1 induced monocyte shape change. The IC50 for MK-0812 in whole blood assays is 8 nM. MK-0812 fully blocks all MCP-1 mediated response in a concentration-dependent manner (IC50: 3.2 nM). This value is similar to the potency observed for the inhibition of 125I-MCP-1 binding by MK-0812 on isolated monocytes (IC50: 4.5 nM) [2]. |
体内活性 | MK-0812 is administered by continuous i.v. infusion to maintain a constant level of the drug in the blood. MK-0812 treatment induces a dose-dependent reduction in circulating Ly6Chi monocytes and a corresponding elevation in the CCR2 ligand CCL2. MK-0812 (30 mg/kg, p.o.) decreases the frequency of Ly6G-Ly6Chi monocytes in the peripheral blood, while no impact on circulating Ly6G+Ly6C+ neutrophil frequency is observed [1][2]. |
分子量 | 587.63 |
分子式 | C28H40F3N3O7 |
CAS No. | 851916-42-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 28 mg/mL (47.65 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7018 mL | 8.5088 mL | 17.0175 mL | 42.5438 mL |
5 mM | 0.3404 mL | 1.7018 mL | 3.4035 mL | 8.5088 mL | |
10 mM | 0.1702 mL | 0.8509 mL | 1.7018 mL | 4.2544 mL | |
20 mM | 0.0851 mL | 0.4254 mL | 0.8509 mL | 2.1272 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MK-0812 Succinate 851916-42-2 Immunology/Inflammation Microbiology/Virology Others CCR CC chemokine receptor MK 0812 Inhibitor MK0812 Succinate MK 0812 Succinate MK0812 MK-0812 inhibit inhibitor